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Summary
Hereditary spastic paraplegia (HSP) is a clinically and
genetically heterogeneous group of disorders character-
ized by insidiously progressive spastic weakness in the
legs. Genetic loci for autosomal dominant HSP exist on
chromosomes 2p, 14q, and 15q. These loci are excluded
in 45% of autosomal dominant HSP kindreds, indicating
the presence of additional loci for autosomal dominant
HSP. We analyzed a Caucasian kindred with autosomal
dominant HSP and identified tight linkage between the
disorder and microsatellite markers on chromosome 8q
(maximum two-point LOD score 5.51 at recombination
fraction 0). Our results clearly establish the existence of
a locus for autosomal dominant HSP on chromosome
8q23-24. Currently this locus spans 6.2 cM between
D8S1804 and D8S1774 and includes several potential
candidate genes. Identifying this novel HSP locus on
chromosome 8q23-24 will facilitate discovery of this
HSP gene, improve genetic counseling for families with
linkage to this locus, and extend our ability to correlate
clinical features with different HSP loci.
Introduction
The hereditary spastic paraplegias (HSP) (MIM 182600,
MIM 182601, MIM 270800, 312920, and MIM
600363) are a group of clinically and genetically diverse
disorders characterized by progressive, usually severe,
lower-extremity spasticity (Rhein 1914; Philipp 1949;
Schwarz and Liu 1956; Roe 1963; Cartlidge and Bone
1973; Behan and Maia 1974; Skre 1974; Sutherland
Received September 28, 1998; accepted for publication November
30, 1998; electronically published January 21, 1999.
Address for correspondence and reprints: Dr. John K. Fink, 5214
CCGCB, 1500 East Medical Center Drive, Ann Arbor, MI 48109-
0940. E-mail: jkfink@umich.edu
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/99/6402-0027$02.00
1975; Holmes and Shaywitz 1977; Boustany et al. 1987;
Keppen et al. 1987; McKusick 1988; Baraitser 1990;
Scheltens et al. 1990; Harding 1993; Polo et al. 1993).
(See reviews by the Hereditary Spastic Paraplegia Work-
ing Group [Fink et al. 1996] and Fink [1997]). HSP is
classified according to both the mode of inheritance (au-
tosomal dominant, autosomal recessive, and X linked)
and whether progressive spasticity occurs in isolation
(“uncomplicated HSP”) or with other neurological
abnormalities (“complicated HSP”), including optic
neuropathy, retinopathy, extrapyramidal disturbance,
dementia, ataxia, icthyosis, mental retardation, and
deafness. The major neuropathological feature of au-
tosomal dominant, uncomplicated HSP is axonal de-
generation that is maximal in the terminal portions of
the longest descending and ascending tracts (crossed and
uncrossed corticospinal tracts to the legs and fasciculus
gracilis, respectively) (Schwarz and Liu 1956; Behan and
Maia 1974; Harding 1993) Spinocerebellar fibers are
involved to a lesser extent.
Each genetic type of HSP (autosomal dominant, re-
cessive, and X-linked) is genetically heterogeneous (see
review by Fink et al. [1996]). Loci for autosomal dom-
inant HSP are present on chromosomes 2p, 14q, and
15q (Hazan et al. 1993, 1994; Figlewicz et al. 1994;
Hentati et al. 1994; Fink et al. 1995a, 1995b; Gispert
et al. 1995; Lennon et al. 1995). Among the 33 HSP
kindreds reported by the Hereditary Spastic Paraplegia
Working Group (Fink et al. 1996), linkage to chromo-
some 2p was the most common, being observed in 15
(45%) of 33 kindreds. Two kindreds (6%) were linked
to chromosome 14q. Linkage to chromosome 15q (Fink
et al. 1995b) was observed in 1 (3%) of 33 kindreds.
Known HSP loci on chromosomes 2p, 14q, and 15q
were excluded in 15 of 33 autosomal dominant HSP
kindreds. The exclusion of known loci in 45% of au-
tosomal dominant HSP kindreds indicates the presence
of additional loci for autosomal dominant HSP. We eval-
uated a white kindred with uncomplicated, autosomal
dominant HSP and excluded linkage to knownHSP loci.
We performed a genomewide search for a novel HSP
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Figure 1 Kindred with HSP linked to chromosome 8q23-24 (SPG8)
locus in this family and observed tight linkage of the
disorder to a group of microsatellite markers loci on
chromosome 8q.
Subjects, Material, and Methods
Subjects
We examined 21 members of a nonconsanguineous
North American kindred of German descent (fig. 1). One
additional subject (subject V-13; see fig. 1) was inter-
viewed but was not examined; medical records from his
referring neurologist were reviewed. Pedigree informa-
tion was obtained from many relatives. Informed con-
sent was obtained from each subject, as specified by the
University of Michigan institutional review board. Sub-
jects were diagnosed according to published criteria
(Fink et al. 1996), at the time of blood collection and
prior to genotyping. Deceased subjects were diagnosed
as “affected” or “unaffected” on the basis of the de-
scriptions of at least two relatives. Age at onset of symp-
toms was obtained by interviewing the living affected
subjects.
We performed genetic-linkage analysis, using 15 living
affected subjects, 4 living unaffected subjects, and 3
spouses of descendants. Marrying-in spouses were
asymptomatic, had normal neurological examinations,
and had no evidence of similar neurological disorders in
their families. We did not include in our analysis either
subjects for whom the diagnosis was uncertain or sub-
jects considered “at risk” of developingHSP (i.e., asymp-
tomatic subjects with normal neurological examinations
who were !50 years of age).
Genotyping and Linkage Analysis
DNA was extracted from peripheral blood leukocytes
as described elsewhere (Bell et al. 1981). Microsatellite
DNA polymorphisms were amplified by PCR, according
to standard procedures. Amplifications were performed
in 25-ml vols in 96-well trays, by Coy and M.J. Research
thermocyclers, for 35 cycles. One primer was labeled
with [g32P]-ATP, by means of T4 polynucleotide kinase.
Amplified DNA was electrophoresed on 7% polyacryl-
amide/6M urea-formamide gels, and alleles were scored
on the basis of autoradiographs.
Two-point linkage analyses were performed by the
MLINK subroutine of the LINKAGE program (Lathrop
et al. 1985), with an autosomal dominant model of dis-
ease inheritance and with a disease-allele frequency of
.001. We assigned a genetic penetrance of .90 for LOD-
score calculations.
Marker-allele frequencies were not calculated from
data for this family, since only three unrelated spouses
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Table 1
Exclusion of Linkage to Known Autosomal Dominant HSP Loci
HSP LOCUS
AND MARKER
(PENETRANCE)
TWO-POINT LOD SCORE AT v 
.001 .05 .1 .2 .3 .4
2p:
D2S352 (.90) 5.45 1.72 .99 .41 .18 .07
D2S367 (.90) 1.22 .26 .34 .27 .16 .07
14q:
D14S269 (.90) 1.94 .33 .12 .01 .03 .01
D14S306 (.90) 6.70 2.24 1.39 .64 .31 .12
D14S288 (.90) 4.17 .97 .51 .17 .06 .02
15q:
D15S122 (.90) 2.12 .53 .32 .15 .07 .02
D15S128 (.908) 1.64 .06 .10 .12 .06 .02
D15S156 (.90) .44 .39 .33 .21 .11 .04
D15S165 (.90) 2.57 .87 .56 .26 .11 .04
were available. Instead, LOD scores were calculatedwith
marker-allele frequencies assumed to be equal. The
LINKMAP program of LINKAGE, used for multipoint
linkage analysis, utilized published locations (Marshfield
Medical Research Foundation) of markers D8S1084,
D8S1799, D8S1179, D8S266, D8S1461, and D8S1774.
Results
Clinical Analysis
HSP was diagnosed in 15 living subjects who devel-
oped insidiously progressive gait disturbance at age
22–60 years (mean age 37.3 years; SD 12.2 years). Neu-
rological examination of affected subjects demonstrated
spastic diplegic gait disturbance (ranging from mild to
profound), frank corticospinal-tract deficits in the lower
extremities (including spasticity, grade 4 hyperreflexia,
and extensor plantar responses), weakness of hip flexion
and ankle dorsiflexion, diminished vibratory sensation
in the feet, and, often, pes cavus. Mild terminal dys-
metria on finger-to-nose testing was noted in several sub-
jects. There was no muscle wasting, with the exception
of mild muscle atrophy, which, when present, was noted
in the shins of subjects in wheelchairs. Bladder distur-
bance (urgency and incontinence) was present in 7 of
15 affected subjects.
We observed one instance of probable incomplete ge-
netic penetrance. Subject V-13 (fig. 1) is unequivocally
affected with insidiously progressive, severe spastic para-
plegia, which began at age 23 years. His mother (subject
IV-15; see fig. 1), who is asymptomatic and whose neu-
rological examination at age 60 years demonstrated only
subtle decreased stride length, is either nonpenetrant or
presymptomatic.
Exclusion Analysis
We tested linkage to microsatellite polymorphisms lo-
cated at known autosomal dominant HSP loci on chro-
mosomes 2p, 14q, and 15q. We observed negative LOD
scores for markers flanking and within these loci (table
1). These data indicated that the disorder in this kindred
was not linked to these known HSP loci.
Genomewide Search for a Novel HSP Locus
We then undertook genomewide genetic-linkage anal-
ysis to identify the novel HSP locus in this family. We
analyzed 284 microsatellite polymorphisms, spaced
5–20 cM throughout the genome, for linkage with the
disorder in this HSP kindred. We observed positive LOD
scores for individual markers located on chromosomes
2, 10, and 18: D2S1391, 3.11 ( ); D10S1709, 2.77v  0
( ); D18S380, 2.04 ( ). However, we observedv  0 v  0
significantly negative LOD scores for markers as close
as 1–2 cM from each of these loci. For example, D2S364
and D2S1787 gave LOD scores of 10.20 and 17.17,
respectively, at and of 2.20 and 3.69, respec-v  0
tively, at ; D10S1739 and D10S159 gave LODv  .10
scores of 3.63 and 10.82, respectively, at andv  0
of 1.34 and 2.68, respectively, at ; D18S870v  .05
and D18S812 gave LOD scores of 4.03 and 3.55,
respectively, at and of 0.74 and 0.38, respec-v  0
tively, at . These data indicated that positive LODv  .05
scores for these single microsatellite markers were simply
random associations observed in a relatively small
kindred.
Linkage to Chromosome 8q
We observed linkage of the disorder to a group of
marker loci mapped to chromosome 8q (table 2). Under
the assumption that genetic penetrance was .90, the
maximum two-point LOD score was 5.51 ( )v  0
for D8S1179 (CHLC.GATA 7G06.P6384). Three ad-
ditional markers—namely, D8S1138 (CHLC.GATA
50B06.P15277), D8S1799 (AFM283xb5), and
D8S1461 (CHLC.ATA 42A09.P34343)—also yielded
two-point LOD scores 13.0 (table 2). Marker D8S266
(AFM151ye3) yielded a two-point LOD score of 2.94
at . A significantly positive two-point LOD scorev  0
was obtained for D8S1138 (LOD score 3.6 at ),v  0
although this marker could not be located precisely on
the same genetic map of this region (MarshfieldMedical
Research Foundation) on which the other markers were
located. However, two-point LOD-score analysis dem-
onstrated that this marker (D8S1138) had no recom-
binations with markers D8S266 and D8S1461, both of
which were located in the nonrecombinant disease
haplotype.
As noted above, we observed one individual (subject
IV-15; see fig. 1) who is either presymptomatic or non-
penetrant. Therefore, we repeated two-point linkage
analysis, assigning genetic penetrances .80 and .70 (table
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Table 2
Results of Two-Point Linkage Analysis for Microsatellite Polymorphisms on
Chromosome 8q23-24
MARKER AND PENETRANCE
TWO-POINT LOD SCORE AT v 
.001 .05 .10 .20 .30 .40
D8S1804 (AFM312yg5):
.9 1.79 1.28 1.50 1.30 .85 .38
.8 1.64 1.36 1.56 1.33 .87 .38
.7 1.54 1.43 1.61 1.35 .87 .38
D8S1138 (CHLC.GATA 50B06.P15277):
.9 3.60 3.19 2.27 1.92 1.11 .45
.8 3.69 3.26 2.82 1.94 1.12 .45
.7 3.75 3.30 2.85 1.96 1.13 .45
D8S1179 (CHCL.GATA 7G06.P6384):
0.9 5.51 4.92 4.33 3.14 1.95 .85
.8 5.39 4.83 4.25 3.07 1.91 .84
.7 5.29 4.73 4.17 3.01 1.87 .82
D8S1799 (AFM283xb5):
.9 3.28 2.91 2.53 1.77 1.07 .47
.8 3.48 3.08 2.68 1.88 1.13 .49
.7 3.28 2.89 2.50 1.74 1.04 .45
D8S266 (AFM151ye3):
.9 2.94 2.64 2.33 1.67 1.02 .46
.8 3.11 2.78 2.43 1.73 1.06 .47
.7 3.24 2.88 2.52 1.78 1.08 .46
D8S1461 (CHLC.ATA 42A09.P34343):
.9 3.09 2.65 2.20 1.37 .67 .19
.8 3.28 2.81 2.34 1.46 .73 .22
.7 2.88 2.45 2.03 1.26 .62 .18
D8S1774 (AFMb321wc1):
.9 2.30 3.47 3.25 2.47 1.58 .71
.8 2.24 3.40 3.18 2.42 1.54 .69
.7 2.19 3.34 3.12 2.37 1.50 .67
2). Even at a lowered penetrance of .70, three markers
with LOD scores 13.0 ( ) remained statisticallyv  0
significant (table 2). The LOD score for D8S266
(AFM151ye3) increased from 2.94 ( ) to 3.24v  0
( ) when penetrance was reduced from .90 to .70.v  0
The most informative marker, D8S1179 (CHLC.GATA
7G06.P6384), did not change substantially when LOD
scores were calculated at a penetrance of either .90 (LOD
score 5.51 at ) or .70 (LOD score 5.29 at ).v  0 v  0
The genotypes for all markers with no recombination
and the two adjacent flanking markers showing obligate
recombinants at D8S1804 and D8S1774 are shownwith
the pedigree in figure 1.
Multipoint linkage analysis was performed for the dis-
ease locus and two adjacent markers at a time, sequen-
tially, for all markers from D8S1799 to D8S266
(D8S1799, D8S1461, D8S1179, and D8S266). Pub-
lished distances between these markers were obtained
from Marshfield Medical Research Foundation (fig. 2).
A genetic penetrance of .90 was used for these calcu-
lations. Multipoint linkage analysis produced a maxi-
mum LOD score of 7.26, at D8S1179.
Discussion
Our data establish the existence of a locus for auto-
somal dominant, uncomplicated HSP, in the telomeric
region of chromosome 8q. Previous physical mapping
(NIH/CEPHCollaborativeMapping Group 1992) of the
microsatellite markers allows us to assign the HSP locus
to chromosome 8q23-24. At present, our data localize
this region to a 6.2-cM interval between D8S1804 and
D8S1774 (fig. 2).
The Genome Database designations for HSP (“spastic
gait” [SPG]) loci are “SPG1” (X linked), “SPG2” (X
linked), “SPG3” (chromosome 14q, autosomal domi-
nant), “SPG4” (chromosome 2p, autosomal dominant),
“SPG5” (chromosome 8q, autosomal recessive), and
“SPG6” (chromosome 15q, autosomal dominant) (see
review by Fink et al. [1996]). It would be appropriate
to designate the recently identified chromosome 16 locus
for autosomal recessive HSP as “SPG7” (De Michele et
al. 1998). We propose that the chromosome 8q23-24
locus for autosomal dominant, uncomplicated HSP be
designated “SPG8.”
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Figure 2 SPG8 locus on chromosome 8q23-24: genetic map.
Locations of genetic markers (Kosambi distances [in cM] are given in
parentheses) were obtained from Marshfield Medical Research Foun-
dation Center for Medical Genetics.
With identification of autosomal dominant HSP loci
on chromosomes 2p, 8q, 14q, and 15q, it is possible to
compare phenotypes in families in which the disorder is
linked to each of these loci and in those families in which
each of these loci is excluded. The disorder in the chro-
mosome 8q–linked family that we studied was insidi-
ously progressive and very severe. Ten of 15 subjects
140 of age required wheelchairs. The average age at
onset of symptoms in this family (37.3 years) was later
than that in the single reported chromosome 15q–linked
family (22.5 years [Fink et al. 1995a]) but was similar
to both that in the chromosome 14q–linked family re-
ported by Hazan et al. (1993) (average age at onset of
symptoms 31.6 years) and that in the four chromosome
2p–linked families reported by Nance et al. (1998) (av-
erage age at onset of symptoms 35 years).
We could discern no clinical features that distin-
guished between the disorder in this chromosome
8q–linked HSP family and those reported in uncompli-
cated autosomal dominant HSP families with linkage to
chromosomes 2p, 14q, or 15q (Fink et al. 1996). This
observation suggests that the different abnormal gene
products responsible for these disorders participate in a
common biochemical cascade that results in a similar
pattern of CNS degeneration. Alternatively, phenotypic
similarity of HSP that links to different loci could be
explained by the presence of a family of structurally
related genes that are present at each HSP locus.
Although not common, genetic anticipation has been
described in HSP (Fink et al. 1996). For example, Niel-
sen et al. (1997, 1998) reported genetic anticipation in
autosomal dominant uncomplicated HSP kindreds in
which the disorder was linked to chromosome 2p. Fur-
thermore, they also observed an expanded trinucleotide
repeat that segregated with the disorder in these kindreds
(Nielsen et al. 1997).
We determined age at onset of symptoms by inter-
viewing the living affected subjects. Estimated age at
onset of symptoms in deceased subjects was not in-
cluded, because this information was considered inac-
curate. Only three sets of living affected parents and their
living affected children were available for which we
could compare age at onset of symptoms in succeeding
generations. Subject IV-13 (fig. 1) had symptom onset
later (age 60 years) than his children (age at onset of
symptoms in subjects V-9, V-10, and V-12 was 40, 38,
and 40 years, respectively). In contrast, the age at onset
of symptoms (28 years) in subject V-6 was similar to
that (age 30 years) in her daughter (subject VI-1). Sim-
ilarly, the age at onset of symptoms (38 years) in subject
V-10 was similar to that (age 30 years) in his son (subject
VI-2). Thus, although we have only limited data, we did
not observe a consistent trend toward progressively
younger age at onset of symptoms in succeeding gen-
erations in this family.
Analysis of candidate genes is an important approach
toward discovery of both the SPG8 gene and genes re-
sponsible for other types of HSP. The distribution of
axonal degeneration to the terminal portions of the long-
est CNS axons raises the possibility that genes involved
in neurotrophic regulation, maintenance of axonal cy-
toskeleton, or axoplasmic flow could be involved. The
defect is quite selective. Pathological changes are con-
fined to central—not peripheral—axons.
Recently, mutations in a novel mitochondrial metal-
loprotease gene (paraplegin) on chromosome 16 were
identified in subjects with autosomal recessiveHSP (Cas-
ari et al. 1998). Evidence of mitochondrial disturbance
was provided by abnormal-appearing mitochondria
(“ragged red fibers”) in the muscle biopsy from two
patients. Although Casari et al. (1998) found evidence
of three structurally related paraplegin-like genes on
chromosomes 4, 10, and 16, there was no evidence of
a homologous gene on chromosome 8. Nonetheless,
both the discovery of the paraplegin gene and evidence
of mitochondrial disturbance in one form of autosomal
recessive HSP provide important insight into biochem-
ical pathways that, if disturbed, could result in HSP’s
selective axonal degeneration.
Analysis of X-linked HSP also suggests a potential
class of candidate genes for autosomal dominant HSP.
Cambi et al. (1995) found a missense mutation in the
proteolipoprotein (PLP) gene coding sequence in affected
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males of one family but not in a second family. Muta-
tions in the two PLP exons also were identified in af-
fected subjects from another, unrelated kindred with un-
complicated X-linked HSP (Dube et al. 1997). Thus, in
these families, uncomplicated X-linked HSP is allelic to
both complicated X-linked HSP (Zatz et al. 1976; Ko-
bayashi et al. 1994) and Pelizaeus-Merzbacher disease,
since they all result from PLP-gene mutations. Uncom-
plicated HSP is characterized by progressive axonal de-
generation, rather than by the primary dysmyelination
characteristic of Pelizeaus-Merzbacher disease. None-
theless, the presence of PLP-gene mutations in X-linked,
uncomplicated HSP indicates that consideration of po-
tential candidate genes should include those involved in
myelin synthesis.
We searched the Genome Database for genes mapped
to the SPG8 locus (D8S1804–D8S1774) on chromo-
some 8q23-24. Interesting and potential candidate genes
among this list include KCNQ3 (the potassium-channel
gene implicated in benign familial neonatal convulsions);
syntrophin beta 1 (SNT2B1), a widely expressed dys-
trophin-associated protein; protein kinase (PTK2); phos-
pholipase, A2 like (PLA2L); phosphodiesterase I/nu-
cleotide pyrophosphatase 2 (PDNP2); and plectin 1
(PLEC1), an intermediate filament–binding protein. Fine
mapping the SPG8 locus and construction of a physical
map across this locus will permit assessment of these
genes, as well as identification and analysis of other po-
tential SPG8 candidate genes. Identification of genetic
mutations responsible for autosomal dominant HSP will
provide insight into the pathophysiology of this condi-
tion and, it is hoped, into other inherited and degener-
ative brain and spinal-cord disorders characterized by
axonal degeneration.
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